Kidswell Bio Corporation (4584) AI Stock Analysis

• Market Cap: ¥13.59B
• Dividend Yield: N/A
• Average Volume (3M): 766.13K
• Price to Earnings (P/E): 258.3
• Beta (1Y): 1.25
• Revenue Growth: 83.60%
• EPS Growth: N/A
• Country: JP
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.20
• Shares Outstanding: 49,611,320
• 10 Day Avg. Volume: 871,200
• 30 Day Avg. Volume: 766,126
• PEG Ratio: 2.17
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 0.89
• P/FCF Ratio: 4.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: ¥261.00 ▲(28.57% Upside)
• Action: Upgraded Date: 01/27/26
• Date: Action: Upgraded 01/27/26

The score is supported most by strong technical momentum and improving cash flow, but is held back by ongoing net losses, leverage risk on the balance sheet, and a relatively expensive valuation (high P/E with no dividend yield).

Positive Factors

Strong revenue growth

Sustained, large revenue growth signals expanding commercial traction and product/service adoption. Over a 2–6 month horizon this supports scaling benefits, improves leverage for fixed costs, and provides a larger base to convert future operational improvements into sustainable profitability and reinvestment.

Operating and free cash flow turned positive

Positive operating and free cash flow represent a durable improvement in cash-generation ability, reducing reliance on external financing. This strengthens runway for clinical and manufacturing investments, lowers near-term funding risk, and increases flexibility to prioritize profitable growth initiatives.

Improved liquidity and reasonable equity funding

A clearer cash buffer and a reasonable equity funding mix support resilience through multi-quarter development cycles. Improved liquidity lowers short-term refinancing risk, enabling continued R&D and scale-up execution while providing optionality for partnerships or targeted capital spending.

Negative Factors

Persistent net losses

Ongoing net losses are a structural constraint: they erode shareholder equity and mean the business remains dependent on external capital. Over months this raises dilution and refinancing risk, complicates long-term planning, and delays the point at which organic earnings can fund growth and R&D.

High debt-to-equity / leverage risk

Material leverage increases financial fixed costs and reduces strategic flexibility. In a development-heavy biotech, high debt magnifies downside from clinical or regulatory delays, can force costly refinancing or covenant pressure, and constrains the company’s ability to invest opportunistically.

Negative margins and operational inefficiencies

Low and negative margins indicate the company still struggles to convert revenue into sustainable profits. Without durable margin expansion, revenue growth may not translate into self-funded development or commercialization, keeping dependence on external capital and pressuring long-term return metrics.

Kidswell Bio Corporation Business Overview & Revenue Model

Company Description

Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Kidswell Bio Corporation generates revenue through the development and commercialization of its regenerative medicine and biopharmaceutical products. The company earns money by licensing its technologies, securing partnerships with other healthcare companies for co-development or distribution, and potentially receiving milestone payments and royalties from successful commercialization of its therapies. Additionally, Kidswell Bio may benefit from government grants or research funding aimed at advancing innovative medical treatments.

Kidswell Bio Corporation Financial Statement Overview

Summary

Strong revenue growth and a clear improvement in cash generation (operating cash flow and free cash flow turned positive) support the score, but persistent net losses and high leverage on the balance sheet materially limit overall financial strength.

Income Statement

Kidswell Bio Corporation has shown significant revenue growth from 2024 to 2025, with revenues more than doubling. However, the company has consistently struggled with profitability, reflected in negative net income over multiple years. The gross profit margin for 2025 is relatively healthy at approximately 32.2%, but the net profit margin remains negative, indicating ongoing challenges in cost management and efficiency. EBIT and EBITDA margins have improved but remain low, suggesting ongoing operational inefficiencies.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio in 2025, indicating potential leverage risks. However, the equity ratio shows a reasonable portion of assets funded by equity. The return on equity remains negative due to sustained net losses. While the company has improved its cash position, indicating better liquidity management, the overall financial stability remains a concern due to high liabilities and negative equity returns.

Cash Flow

The cash flow statement shows a substantial improvement in operating cash flow, turning positive in 2025, which is a strong indicator of improved cash management. Free cash flow has seen significant growth, moving from negative to positive, reflecting a more efficient use of capital expenditures. However, the free cash flow to net income ratio is skewed by the negative net income, and while operating cash flow has improved, the company still faces challenges in generating consistent profitability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.32B	5.08B	2.43B	2.78B	1.57B	996.54M
Gross Profit	2.01B	1.64B	1.04B	1.53B	1.02B	876.97M
EBITDA	399.96M	116.26M	-1.38B	-620.45M	-531.89M	-983.00M
Net Income	312.68M	-21.14M	-1.42B	-657.43M	-550.86M	-1.00B
Balance Sheet
Total Assets	6.58B	7.01B	5.09B	3.89B	3.47B	3.93B
Cash, Cash Equivalents and Short-Term Investments	2.84B	3.00B	2.23B	1.07B	1.16B	1.46B
Total Debt	1.55B	1.84B	2.58B	1.95B	700.00M	1.10B
Total Liabilities	4.53B	5.60B	4.25B	2.66B	1.77B	2.32B
Stockholders Equity	2.05B	1.41B	831.47M	1.23B	1.70B	1.61B
Cash Flow
Free Cash Flow	0.00	930.26M	-453.63M	-1.42B	-1.17B	-1.27B
Operating Cash Flow	0.00	936.71M	-453.63M	-1.42B	-1.17B	-1.27B
Investing Cash Flow	0.00	65.08M	0.00	-28.82M	526.51M	-22.29M
Financing Cash Flow	0.00	-240.06M	1.62B	1.36B	369.08M	718.35M

Kidswell Bio Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 203.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4584, the sentiment is Positive. The current price of 203 is below the 20-day moving average (MA) of 256.00, below the 50-day MA of 241.32, and below the 200-day MA of 249.89, indicating a bullish trend. The MACD of 3.29 indicates Positive momentum. The RSI at 51.81 is Neutral, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4584.

Kidswell Bio Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	59 Neutral	¥13.59B	258.32	―	―	83.60%	―
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	55 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4593	48 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%

Kidswell Bio Corporation Corporate Events

Kidswell Bio Narrows Losses on Strong Sales, Raises Capital Ratio but Keeps Dividend at Zero

Kidswell Bio reported consolidated net sales of ¥5,018 million for the nine months ended December 31, 2025, up 65.3% year on year, while posting an operating profit of ¥84 million and a net loss attributable to owners of the parent of ¥142 million, an improvement from the previous year’s deeper loss. The company’s financial position strengthened, with total assets of ¥6,319 million, shareholders’ equity of ¥1,879 million, and its capital adequacy ratio rising to 29.7%, while it maintained a zero-dividend policy and forecast full-year net sales of ¥6.0–6.5 billion and operating income in a range of a ¥100 million loss to a ¥100 million profit, underscoring a transition phase toward potential profitability.

Kidswell Bio will not pay dividends for FY 2025 or FY 2026, as it prioritizes reinforcing its balance sheet and funding operations. The forecast range for operating income reflects uncertainty in earnings visibility but also signals management’s expectation that strong sales growth could bring the business close to break-even on a full-year basis, a key consideration for investors watching its path to sustainable profitability.

The most recent analyst rating on (JP:4584) stock is a Hold with a Yen256.00 price target. To see the full list of analyst forecasts on Kidswell Bio Corporation stock, see the JP:4584 Stock Forecast page.

Kidswell Bio Outlines FY2025 Q3 Results and Strategic Focus

Kidswell Bio Corporation reported its financial results for the third quarter of fiscal 2025, outlining financial highlights alongside progress in its biosimilars and S-Quatre cell therapy businesses. The company also discussed its broader corporate strategy and investor relations activities, signaling continued efforts to strengthen its operational footprint and position in pediatric and family-focused healthcare solutions.

The most recent analyst rating on (JP:4584) stock is a Hold with a Yen256.00 price target. To see the full list of analyst forecasts on Kidswell Bio Corporation stock, see the JP:4584 Stock Forecast page.